Gabriela Valle-Núñez

Gabriela Valle-Núñez

Auto-generated profile, based on publicly available information

Gabriela Valle-Núñez

DIFACQUIM Research Group, Department of Pharmacy, School of Chemistry, Universidad Nacional Autónoma de México, Avenida Universidad 3000, Mexico City 04510, Mexico

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 April 2025 in Digital Discovery
Verified
Journal Article
Open access
PDF file
GVGabriela Valle-Núñez
Gabriela Valle-Núñez
RCRaziel Cedillo-González
Raziel Cedillo-González
JAJuan Felipe Avellaneda-Tamayo
Juan Felipe Avellaneda-Tamayo
FSFernanda I. Saldívar-González
Fernanda I. Saldívar-González
DPDiana L. Prado-Romero
Diana L. Prado-Romero
JMJose Medina-Franco
Jose Medina-Franco
Viral infections represent a significant global health concern.

4 February 2025 in ChemRxiv
Verified
Preprint
Open access
PDF file
GVGabriela Valle-Núñez
Gabriela Valle-Núñez
RCRaziel Cedillo-González
Raziel Cedillo-González
JAJuan F. Avellaneda-Tamayo
Juan F. Avellaneda-Tamayo
FSFernanda Saldivar
Fernanda Saldivar
DPDiana L. Prado-Romero
Diana L. Prado-Romero
JMJose Medina-Franco
Jose Medina-Franco
Viral infections represent a significant global health concern; therefore, herein we seek to design compound libraries with prospective antiviral activity. Viral diseases can range from mild symptoms to life-threatening conditions, and the impact of these infections has grown due to increased contagious rates driven by globalization. A prime example is the SARS-CoV-2 pandemic, which emphasized the urgent need to design and develop new antiviral drugs. This study aimed to generate a curated data set of compounds relevant to respiratory infections, focusing on predicting their antiviral activity. Specifically, the study leverages ML classification models to evaluate focused and on-demand compound libraries targeting pathways associated with viral respiratory infections. ML models were trained based on the antiviral biological activity related to respiratory diseases deposited on a major public compound database annotated with biological activity. The models were validated and retrained to classify and design antiviral-focused libraries on seven respiratory targets.